Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Genetic Measurements in Blood Cells of Children Taking Adderall or Methylphenidate
A completed clinical trial evaluating genetic measurements in blood cells of children taking ADHD medications Adderall or methylphenidate.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Treatment of Patients With Alcoholism and Attention Deficit Disorder [Phase 4]
A Phase 4 clinical trial evaluating treatments for alcoholism and attention-deficit/hyperactivity disorder has completed.
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Studies of Measures of Attention
A National Institute on Deafness and Other Communication Disorders–sponsored clinical trial evaluating measures of attention related to Atte…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: A Controlled Study of Parent Training in the Treatment of ADHD in Young Children [NA]
Clinical trial has completed a controlled study evaluating parent training as treatment for attention-deficit/hyperactivity disorder in youn…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Brain Imaging in Children With AD/HD
A completed clinical trial assessing brain imaging in children with attention-deficit/hyperactivity disorder and healthy controls.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Omega-3 Supplementation to ADHD Medication in Children [Phase 4]
Phase 4 trial evaluating omega-3 fatty acid supplementation in children taking ADHD medication. Results from the study have been posted.
-
FDA approval · 2017-06-20FDA Approved: MYDAYIS — Original Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved the original application for MYDAYIS, a mixed amphetamine salts product, for the treatment of attention deficit hyperactivi…
-
FDA approval · 2017-06-19FDA Approved: COTEMPLA XR-ODT — Original Application (Neos Therapeutics Brands, LLC)
The FDA approved Cotempla XR-ODT (methylphenidate) through an original NDA for the treatment of attention-deficit/hyperactivity disorder. Th…
-
CLINICAL_TRIALS trial_result · 2017-06-16Clinical Trial Update: Evaluation of Use of Brain Activity Monitoring Dynamics in ADHD [NA]
This clinical trial evaluating brain activity monitoring dynamics in Attention-deficit/hyperactivity disorder has been completed.
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) [Phase 3]
Phase 3 trial assessing safety and efficacy of SHP465 in adults with ADHD completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder [Phase 4]
Phase 4 clinical trial comparing single vs. combination medication treatment for children with Attention Deficit Disorder with Hyperactivity…
-
CLINICAL_TRIALS trial_result · 2017-06-05Clinical Trial Update: Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study [Phase 4]
A Phase 4 pilot trial explored dose-response effects of Quillivant XR in children with ADHD and autism, with results posted in 2017.
-
CLINICAL_TRIALS research · 2017-06-05Clinical Trial Update: Psychiatric Assessment Of Parents Of Children With ADHD
This clinical trial update describes a study evaluating the psychiatric status of parents of children with ADHD, sponsored by Assiut Univers…
-
CLINICAL_TRIALS trial_result · 2017-05-31Clinical Trial Update: Effects of Cognitive Training on Academic Task Performance in Attention Deficit Hyperactivity Disorder (ADHD) [NA]
This update notes that a clinical trial assessing the impact of cognitive training on academic task performance in individuals with ADHD has…
-
FDA approval · 2017-05-30FDA Approved: ATOMOXETINE — Original Application (Northstar Rx LLC)
FDA approved the original application for a generic atomoxetine product by Northstar Rx LLC.
-
FDA approval · 2017-05-30FDA Approved: ATOMOXETINE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s original ANDA for atomoxetine, establishing a generic version of the ADHD medication.
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: The Effects of Yoga on Attention, Impulsivity and Hyperactivity in Pre-school Age Children [NA]
This clinical trial status update indicates a completed study evaluating the effects of yoga on attention, impulsivity, and hyperactivity in…
-
FDA approval · 2017-05-30FDA Approved: ATOMOXETINE HYDROCHLORIDE — Original Application (Apotex Corp.)
FDA approved Apotex Corp.'s generic atomoxetine hydrochloride as an original ANDA for the treatment of attention-deficit/hyperactivity disor…
-
FDA approval · 2017-05-30FDA Approved: ATOMOXETINE — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's original application for atomoxetine (generic). Atomoxetine is used to treat attention deficit hyper…
-
FDA approval · 2017-05-19FDA Approved: DEXEDRINE SPANSULE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for Dexedrine Spansule (dextroamphetamine sulfate) submitted by Amneal Pharmaceuticals LLC.
-
FDA approval · 2017-05-19FDA Approved: STRATTERA — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Strattera (atomoxetine hydrochloride) filed by Eli Lilly and Company.
-
CLINICAL_TRIALS trial_result · 2017-05-19Clinical Trial Update: Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits [Phase 3]
A Phase 3 trial evaluating treatment for traumatic brain injury-related attention deficits was terminated. Results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-05-18Clinical Trial Update: Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe [Phase 3]
Phase 3 trial update describing access to extended-release guanfacine HCl for European participants from SPD503-315/316; results posted in 2…
-
FDA approval · 2017-05-12FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for DYANAVEL XR (amphetamine) submitted by NextWave Pharmaceuticals, Inc. The action concerns th…
-
FDA approval · 2017-05-11FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (KVK-TECH, INC.)
FDA approved the original application for methylphenidate hydrochloride from KVK-Tech, Inc., granting a generic version of this stimulant fo…